While Ionis Pharmaceuticals Inc has overperformed by 1.62%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, IONS fell by -28.00%, with highs and lows ranging from $52.34 to $23.95, whereas the simple moving average fell by -21.99% in the last 200 days.
On April 07, 2025, H.C. Wainwright started tracking Ionis Pharmaceuticals Inc (NASDAQ: IONS) recommending Buy. A report published by Redburn Atlantic on March 31, 2025, Initiated its previous ‘Neutral’ rating for IONS. BMO Capital Markets also Downgraded IONS shares as ‘Market Perform’, setting a target price of $60 on the company’s shares in a report dated August 02, 2024. Leerink Partners July 24, 2024d the rating to Outperform on July 24, 2024, and set its price target from $53 to $62. Jefferies initiated its ‘Buy’ rating for IONS, as published in its report on July 16, 2024. Bernstein’s report from June 14, 2024 suggests a price prediction of $44 for IONS shares, giving the stock a ‘Mkt Perform’ rating. Wolfe Research also rated the stock as ‘Outperform’.
Analysis of Ionis Pharmaceuticals Inc (IONS)
Further, the quarter-over-quarter decrease in sales is -30.15%, showing a negative trend in the upcoming months.
To gain a thorough understanding of Ionis Pharmaceuticals Inc’s future performance, several well-rounded types of analysis and research techniques can be used, with equity being among the most crucial. The goal here is to ensure that your current return on equity of -93.03% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 8.43, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
It is also very valuable to look at average volume as an indicator of volatility for a stock, and IONS is recording an average volume of 1.75M. On a monthly basis, the volatility of the stock is set at 5.65%, whereas on a weekly basis, it is put at 3.35%, with a gain of 4.30% over the past seven days. Furthermore, long-term investors anticipate a median target price of $55.61, showing growth from the present price of $29.57, which can serve as yet another indication of whether IONS is worth investing in or should be passed over.
How Do You Analyze Ionis Pharmaceuticals Inc Shares?
The number of employees owning shares of the company should also be considered in addition to the fundamentals. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 2.76%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 100.37% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
IONS shares are owned by institutional investors to the tune of 100.37% at present.
